Kathleen Behr1, Carmen M Kavali2, Girish Munavalli3, Craig F Teller4, Steve Yoelin5, Laura Breshears6, Sara Sangha7. 1. Private Practice (Behr Laser & Skin Care Center), Fresno, California. 2. Private Practice (Kavali Plastic Surgery and Skin Renewal Center), Atlanta, Georgia. 3. Private Practice (Dermatology, Laser & Vein Specialists of the Carolinas), Charlotte, North Carolina. 4. Private Practice (Bellaire Dermatology Associates), Bellaire, Texas. 5. Private Practice (Medical Associates, Inc.), Newport Beach, California. 6. Evidence Scientific Solutions, Philadelphia, Pennsylvania. 7. Medical Affairs, Allergan plc, Irvine, California.
Abstract
BACKGROUND: Submental fat (SMF) can negatively affect perceptions of health and attractiveness. The Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR) was designed to understand SMF treatment in clinical practice. OBJECTIVE: To report efficacy, treatment characteristics, and safety associated with real-world use of ATX-101 (deoxycholic acid injection). METHODS: CONTOUR enrolled adults considering treatment for SMF reduction. ATX-101-treated patients who completed the end-of-treatment questionnaire were divided into those who ended treatment because they met their treatment goals (n = 197) and those who did not (n = 196). RESULTS: Patients who met their goals (a more defined jawline, looking younger, and looking thinner) were more likely to have less SMF at baseline and to receive ≥2 ATX-101 treatments. More patients who met their goals achieved clinically meaningful reduction in SMF and reported increased satisfaction with their appearance (90% vs 57%). Moderate and severe patients' ATX-101 volume was similar for both those who met goals and those who did not, but extreme patients who met their goals required 10 mL more than those patients who did not. CONCLUSION: Careful patient selection, adequate volume administration, and an appropriate number of treatments (dependent on baseline SMF severity) contribute to successful outcomes with ATX-101.
BACKGROUND: Submental fat (SMF) can negatively affect perceptions of health and attractiveness. The Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR) was designed to understand SMF treatment in clinical practice. OBJECTIVE: To report efficacy, treatment characteristics, and safety associated with real-world use of ATX-101 (deoxycholic acid injection). METHODS: CONTOUR enrolled adults considering treatment for SMF reduction. ATX-101-treated patients who completed the end-of-treatment questionnaire were divided into those who ended treatment because they met their treatment goals (n = 197) and those who did not (n = 196). RESULTS:Patients who met their goals (a more defined jawline, looking younger, and looking thinner) were more likely to have less SMF at baseline and to receive ≥2 ATX-101 treatments. More patients who met their goals achieved clinically meaningful reduction in SMF and reported increased satisfaction with their appearance (90% vs 57%). Moderate and severe patients' ATX-101 volume was similar for both those who met goals and those who did not, but extreme patients who met their goals required 10 mL more than those patients who did not. CONCLUSION: Careful patient selection, adequate volume administration, and an appropriate number of treatments (dependent on baseline SMF severity) contribute to successful outcomes with ATX-101.
Authors: Craig F Teller; Annie Chiu; Cameron D Chesnut; Deborah Sherman; José Raul Montes; Sara Gaspard; Terrence Keaney; Neil S Sadick; Steve Yoelin; Sara Sangha; Sachin M Shridharani Journal: Plast Reconstr Surg Glob Open Date: 2021-07-12